Anti-Viral Vaccine Control of EB Virus-Associated Cancers

  • M. A. Epstein
Part of the NATO ASI Series book series (NSSA, volume 120)


Over the past 21 years Epstein-Barr (EB) virus (1) has been implicated by a huge body of evidence (2,3) in the causation of two important human cancers, endemic Burkit’s lymphoma (BL) (4) which provides the paradigm for virus-induced tumours in man (5), and undifferentiated nasopharyngeal carcinoma (NPC) (6) which has a high incidence amongst a significant section of the world population. More recently, the virus has also been found to be associated with the lymphomas which arise with undue frequency in immunosuppressed organ graft patients (7–9), and in individuals suffering from AIDS (10).


Malignant Lymphoma None None Raji Cell Normal Control Animal Herpesvirus Saimiri 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M. A. Epstein, B. G. Achong, and Y. M. Barr, Virus particles in cultured lymphoblasts from Burkitt’s lymphoma, Lancet, 1: 702 (1964).PubMedCrossRefGoogle Scholar
  2. 2.
    M. A. Epstein, and B. G. Achong, eds., “The Epstein-Barr virus”, Springer, Berlin, Heidelberg, and New York (1979).Google Scholar
  3. 3.
    M. A. Epstein, and B. G. Achong, eds., “The Epstein-Barr virus: recent advances”, Heinemann, London in press (1985).Google Scholar
  4. 4.
    D. Burkitt, A lymphoma syndrome in tropical Africa, in: “International review of experimental pathology”, 2, G. W. Richter, and M. A. Epstein, eds., Academic Press, New York and London (1963).Google Scholar
  5. 5.
    G. M. Lenoir, G. T. O’Connor, and C. L. M. Olweny, eds., “Burkitt’s lymphoma: a human cancer model”, IARC, Lyon (1985).Google Scholar
  6. 6.
    K. Shanmugaratnam, Studies on the etiology of nasopharyngeal carcinoma, in: “International review of experimental pathology”, 10, G. W. Richter, and M. A. Epstein, eds., Academic Press, New York and London (1971).Google Scholar
  7. 7.
    I. Penn, Malignancies associated with immunosuppressive or cytotoxic therapy, Surgery, 83: 492 (1978).PubMedGoogle Scholar
  8. 8.
    L. J. Kinlen, A. G. R. Shiel, J. Peto, and R. Doll, Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs, Brit. Med. J., 2: 1461 (1979).PubMedCrossRefGoogle Scholar
  9. 9.
    J. Weintraub, and R. A. Warnke, Lymphoma in cardiac allotransplant recipients: clinical and histological features and immunological phenotype, Transplantation, 33: 347 (1982).PubMedCrossRefGoogle Scholar
  10. 10.
    J. L. Ziegler, W. L. Drew, R. C. Miner, L. Mintz, E. Rosenbaum, J. Gershon, E. T. Lennette, J. Greenspan, E. Shillitoe, J. Beckstead, C. Casavant, and K. Yamamoto, Outbreak of Burkitt-like lymphoma in homosexual men, Lancet, 11: 631 (1982).CrossRefGoogle Scholar
  11. 11.
    G. M. Lenoir, J. L. Preud’homme, A. Bernheim, and R. Berger, Correlation between immunoglobulin light chain expression and variant translocation in Burkitt’s lymphoma, Nature, 298: 474 (1982).PubMedCrossRefGoogle Scholar
  12. 12.
    R. Dalla-Favera, M. Bregni, J. Erikson, D. Patterson, R. C. Gallo, and C. M. Croce, Human c-myc one gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells, Proc. Nat. Acad. Sci. USA, 79: 7824 (1982).PubMedCrossRefGoogle Scholar
  13. 13.
    R. Traub, I. Kirsch, C. Morton, G. Lenoir, D. Swan, S. Tronick, S. Aaronson, and P. Leder, Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt’s lymphoma and murine plasmacytoma cells, Proc. Nat. Acad. Sci. USA, 79: 7837 (1982).CrossRefGoogle Scholar
  14. 14.
    A. Diamond, G. M. Cooper, J. Ritz, and M.-A. Lane, Identification and molecular cloning of the human Blym transforming gene activated in Burkitt’s lymphomas, Nature, 305: 112 (1983).PubMedCrossRefGoogle Scholar
  15. 15.
    P. H. Duesberg, Activated proto-onc genes: sufficient or necessary for cancer? Science, 228: 669 (1985).PubMedCrossRefGoogle Scholar
  16. 16.
    M. L. Cleary, M. A. Epstein, S. Finerty, R. F. Dorfman, G. W. Bornkamm, J. K. Kirkwood, A. J. Morgan, and J. Sklar, Individual tumours of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones, Science, 228: 722 (1985).PubMedCrossRefGoogle Scholar
  17. 17.
    G. Miller, Biology of the Epstein-Barr virus, in: “Viral oncology”, G. Klein, ed., Raven Press, New York (1980).Google Scholar
  18. 18.
    M. Zerbini, and I. Ernberg, Can Epstein-Barr virus infect and transform all,the B-lymphocytes in human cord blood ? J. Gen. Virol., 64: 539 (1983).PubMedCrossRefGoogle Scholar
  19. 19.
    D. P. Burkitt, Etiology of Burkitt’s lymphoma - an alternative hypothesis to a vectored virus, J. Nat. Cancer Inst., 42: 19 (1969).PubMedGoogle Scholar
  20. 20.
    A. B. Rickinson, D. J. Moss, L. E. Wallace, M. Rowe, I. S. Misko, M. A. Epstein, and J. H. Pope, Long term T-cell mediated immunity to Epstein-Barr virus, Cancer Res., 41: 4216 (1981).PubMedGoogle Scholar
  21. 21.
    H. C. Whittle, J. Brown, K. marsh, B. M. Greenwood, P. Seidelin, H. Tighe, and L. Wedderburn, T cell control of B cells infected with EB virus is lost during P. falciparum malaria, Nature, 312: 449 (1984).PubMedCrossRefGoogle Scholar
  22. 22.
    J. S. H. Gaston, A. B. Rickinson, and M. A. Epstein, Epstein-Barrvirus-specific T-cell memory in renal-allograft recipients under long-term immunosuppression, Lancet, 1: 923 (1982).PubMedCrossRefGoogle Scholar
  23. 23.
    M. A. Epstein, Burkitt’s lymphoma - clues to the role of malaria, Nature, 312: 398 (1984).PubMedCrossRefGoogle Scholar
  24. 24.
    G. Klein, The relationship of the virus to nasopharyngeal carcinoma, in: “The Epstein-Barr virus”, M. A. Epstein, and B. G. Achong, eds., Springer, Berlin, Heidelberg and New York, (1979).Google Scholar
  25. 25.
    Y. Ito, M. Kawanishi, T. Harayama, and S. Takabayashi, Combined effects of the extracts from Croton tiglium, Euphorbia lathyris, or Euphorbia tinucalli and n-butyrate on Epstein-Barr virus expression in human lymphoblastoid P3HR-1 and Raji cells, Cancer Letters, 12: 173 (1981).CrossRefGoogle Scholar
  26. 26.
    Y. Leng, L. G. Zhang, H. Y. Li, M. G. Jan, Q. Zhang, Y. S. Wang, and G. R. Su, Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China, Int. J. Cancer, 29: 139 (1982).CrossRefGoogle Scholar
  27. 27.
    M. A. Epstein, Epstein-Barr virus - is it time to develop a vaccine program ? J. Nat. Cancer Inst., 56: 697 (1976).PubMedGoogle Scholar
  28. 28.
    A. Lanier, T. Bender, M. Talbot, S. Wilmet, C. Tschopp, W. Henle, G. Henle, D. Ritter, and P. Terasaki, Nasopharyngeal carcinoma in Alaskan Eskimos, Indians and Aleuts: a review of cases and study of Epstein-Barr virus, HLA and environmental risk factors, Cancer, 46: 2100 (1980).PubMedCrossRefGoogle Scholar
  29. 29.
    M. Cammoun, G. V. Hoerner, and N. Mourali, Tumors of the nasopharynx in Tunisia: an anatomic and clinical study based on 143 cases, Cancer, 33: 184 (1974).PubMedCrossRefGoogle Scholar
  30. 30.
    P. Clifford, A review: on the epidemiology of nasopharyngeal carcinoma, Int. J. Cancer, 5: 287 (1970).PubMedCrossRefGoogle Scholar
  31. 31.
    L. N. Payne, J. A. Frazier, and P. C. Powell, Pathogenesis of Mareks disease, in: “International review of experimental pathology”, 16, G. W7-Richter, and M. A. Epstein, eds., Academic Press, New York and London (1976).Google Scholar
  32. 32.
    A. E. Churchill, L. N. Payne, and R. C. Chubb, Immunization against Marek’s disease using a live attenuated virus, Nature, 221: 744 (1969).PubMedCrossRefGoogle Scholar
  33. 33.
    W. Okazaki, H. G. Purchase, and B. R. Burmester, Protection against Marek’s disease by vaccination with a herpesvirus of turkeys, Avian Dis., 14: 413 (1970).PubMedCrossRefGoogle Scholar
  34. 34.
    L. V. Melendez, R. D. Hunt, M. D. Daniel, F. G. Garcia, and C. E. O. Fraser, Herpesvirus saimiri. U. An experimental induced primate disease resembling reticulum cell sarcoma, Lab. Animal Care, 19: 378 (1969).Google Scholar
  35. 35.
    R. Laufs, and H. Steinke, Vaccination of non-human primates against malignant lymphoma, Nature, 253: 71 (1975).PubMedCrossRefGoogle Scholar
  36. 36.
    O. R. Kaaden, and B. Dietzschold, Alterations of the immunological specificity of plasma membranes of cells infected with Marek’s disease and turkey herpesviruses, J. Gen. Virol., 25: 1 (1974).PubMedCrossRefGoogle Scholar
  37. 37.
    F. Lesnick, and L. J. N. Ross, Immunization against Marek’s disease using Marek’s disease virus-specific antigens free from infectious virus, Int. J. Cancer, 16: 153 (1975).CrossRefGoogle Scholar
  38. 38.
    G. Pearson, F. Dewey, G. Klein, G. Henle, and W. Henle, Relation between neutralization of Epstein-Barr virus and antibodies to cell membrane antigens, J. Nat. Cancer Inst., 45: 989 (1970).PubMedGoogle Scholar
  39. 39.
    L. Gergely, G. Klein, and I. Ernberg, Appearance of Epstein-Barr virus associated antigens in infected Raji cells, Virology, 45: 10 (1971).PubMedCrossRefGoogle Scholar
  40. 40.
    G. Pearson, G. Henle, and W. Henle, Production of antigens associated with Epstein-Barr virus in experimentally infected lymphoblastoid cell lines, J. Nat. Cancer Inst., 46: 1243 (1971).PubMedGoogle Scholar
  41. 41.
    A. de Schryver, G. Klein, J. Hewetson, J. Rocchi, W. Henle, G. Henle, D. J. Moss, and J. H. Pope, Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti MA), Int. J. Cancer, 13: 353 (1974).PubMedCrossRefGoogle Scholar
  42. 42.
    L. F. Qualtiere, and G. Pearson, Epstein-Barr virus-induced membrane antigens from EBV-superinfected Raji cells, Int. J. Cancer, 23: 808 (1979).PubMedCrossRefGoogle Scholar
  43. 43.
    B. C. Strnad, R. H. Neubauer, H. Rabin, and R. A. Mazur, Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins, J. Virol., 32: 885 (1979).PubMedGoogle Scholar
  44. 44.
    D. A. Thorley-Lawson, and C. M. Edson, The polypeptides of the Epstein-Barr virus membrane antigen complex, J. Virol., 32: 458 (1979).PubMedGoogle Scholar
  45. 45.
    L. F. Qualtiere, and G. R. Pearson, Radioimmune precipitation study comparing the Epstein-Barr virus membrane antigens expressed on P3HR-1 virus-superinfected Raji cells to those expressed in a B95–8 virus-transformed producer culture activated with tumor-promoting agent (TPA), Virology, 102: 360 (1980).PubMedCrossRefGoogle Scholar
  46. 46.
    J. R. North, A. J. Morgan, and M. A. Epstein, Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides, Int. J. Cancer, 26: 231 (1980).PubMedCrossRefGoogle Scholar
  47. 47.
    G. J. Hoffman, S. G. Lazarowitz, and S. D. Hayward, Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen, Proc. Nat. Acad. Sci. USA, 77: 2979 (1980).PubMedCrossRefGoogle Scholar
  48. 48.
    D. A. Thorley-Lawson, and K. Geilinger, Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity, Proc. Nat. Acad. Sci. USA, 77: 5307 (1980)PubMedCrossRefGoogle Scholar
  49. 49.
    J. R. North, A. J. Morgan, J. L. Thompson, and M. A. Epstein, Purified EB virus gp340 induces potent virus-neutralizing antibodies when incorporated in liposomes, Proc. Nat. Acad Sci. USA, 79: 7504 (1982).PubMedCrossRefGoogle Scholar
  50. 50.
    A. J. Morgan, M. A. Epstein, and J. R. North, Comparative immunogenicity studies on Epstein-Barr (EB) virus membrane antigen (MA) with novel adjuvants in mice, rabbits and cottontop tamarine J. Med. Virol., 13: 281 (1984).PubMedCrossRefGoogle Scholar
  51. 51.
    M. A. Epstein, R. D. Hunt, and H. Rabin, Pilot experiments with EB virus in owl monkeys (Aotus trivirgatus) I. Reticuloproliferative disease in an inoculated animal, I.t. J. Cancer, 12: 309 (1973).Google Scholar
  52. 52.
    M. A. Epstein, H. Rabin, G. Ball, and L. V. Melendez, Pilot experiments with EB virus in owl monkeys (Aotus trivirgatus) II. EB virus in a cell line from an animal with reticuloproliferative disease, Int. J. Cancer, 12: 319 (1973).PubMedCrossRefGoogle Scholar
  53. 53.
    M. A. Epstein, H. zur Hausen, G. Ball, and H. Rabin, Pilot experiments with EB virus in owl monkeys (Aotus trivirgatus) III. Serological and biochemical findings in an animal with reticuloproliferative disease, Int. J. Cancer, 15: 17 (1975).PubMedCrossRefGoogle Scholar
  54. 54.
    T. Shope, D. Dechairo, and G. Miller, Malignant lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus, Proc. Nat. Acad. Sci. USA, 70: 2487 (1973).PubMedCrossRefGoogle Scholar
  55. 55.
    G. Miller, T. Shope, D. Coope, L. Waters, J. Pagano, G. W. Bornkamm, and W. Henle, Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum, antibody responses, demonstration of viral DNA, and characterization of viruses, J. Exp. Med., 145: 948 (1977).PubMedCrossRefGoogle Scholar
  56. 56.
    G. Miller, Experimental carcinogenicity by the virus in vivo, in: “The Epstein-Barr virus”, M. A. Epstein, and B. G. Achong, eds., Springer, Berlin, Heidelberg and New York (1979).Google Scholar
  57. 57.
    N. S. F. Ma, Chromosome evolution in the owl monkey, Aotus, Amer. J. Phys. Anthropol., 54: 293 (1981).CrossRefGoogle Scholar
  58. 58.
    N. S. F. Ma, T. C. Jones, A. C. Miller, L. M. Morgan, and E. A. Adams, Chromosome polymorphism and banding patterns in the owl monkey (Aotus), Lab. Animal Sci., 26: 1022 (1976).Google Scholar
  59. 59.
    N. S. F. Ma, R. N. Rossan, S. T. Kelley, J. S. Harper, M. T. Bedard, and T. C. Jones, Banding patterns of the chromosomes of two new karyotypes of the owl monkey, Aotus, captured in Panama, J. Med. Primatol., 7: 146 (1978).PubMedGoogle Scholar
  60. 60.
    H. M. Brand, Husbandry and breeding of a newly established colony of cotton-topped tamarins (Saguinus oedipus). Lab. Animals, 15: 7 (1981).CrossRefGoogle Scholar
  61. 61.
    J. K. Kirkwood, M. A. Epstein, and A. J. Terlecki, Factors influencing population growth of a colony of cotton-top tamarins, Lab. Animals, 17: 35 (1983).CrossRefGoogle Scholar
  62. 62.
    J. K. Kirkwood, Effects of diet on health, weight and litter size captive cotton-top tamarins Saguinus oedipus oedipus, Primates, 24: 515 (1983).CrossRefGoogle Scholar
  63. 63.
    J. K. Kirkwood, and S. J. Underwood, Energy requirements of captive cotton-top tamarins (Saguinus oedipus oedipus), Folia Primatolog. 42: 180 (1984).CrossRefGoogle Scholar
  64. 64.
    J. K. Kirkwood, M. A. Epstein, A. J. Terlecki, and S. J. Underwood, Rearing a second generation of cotton-top tamarins Saguinus oedipus oedipus, Lab. Animals, in press (1985).Google Scholar
  65. 65.
    D. J. Moss, and J. H. Pope, Assay of the infectivity of Epstein-Barr virus by transformation of human leucoytes in vitro, J. Gen. Virol., 17: 233 (1972).PubMedCrossRefGoogle Scholar
  66. 66.
    R. F. Dorfman, J. S. Burke, and S. Berard, A working formulation of non-Hodgkins lymphomas: background, recommendations, histological criteria, and relationship to other classifications, in: “Malignant lymphomas”, S. Rosenberg, and H. Kaplan, eds., Academic Press, New York and London (1982).Google Scholar
  67. 67.
    G. W. Bornkamm, C. Desgranges, and L. Gissmann, Nucleic acid hybridization for the detection of viral genomes, Curr. Topics Microbiol. Immunol., 104: 287 (1983).CrossRefGoogle Scholar
  68. 68.
    A. Arnold, J. Cossman, A. Bakhshi, E. S. Jaffe, T. A. Waldmann, and S. J. Korsmeyer, Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms, New Engl. J. Med., 309: 1593 (1983).Google Scholar
  69. 69.
    M. L. Cleary, J. Chao, R. Warnke, and J. Sklar, Immunoglobulin gene rearrangement as a diagnostic criterion of B cell lymphoma, Proc. Nat. Acad. Sci. USA, 81: 593 (1984).PubMedCrossRefGoogle Scholar
  70. 70.
    J. R. North, A. J. Morgan, J. L. Thompson, and M. A. Epstein, Quantification of an EB virus-associated membrane antigen (MA) component, J. Virol. Methods, 5: 55 (1982).PubMedCrossRefGoogle Scholar
  71. 71.
    G. Miller, T. Shope, H. Lisco, D. Stitt, and M. Lipman, Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes, Proc. Nat. Acad. Sci. USA, 69: 383 (1972).PubMedCrossRefGoogle Scholar
  72. 72.
    B. Bowen, J. Steinberg, U. K. Laemmli, and H. Weintraub, The detection of DNA binding proteins by protein blotting, Nucleic Acids Res., 8: 1 (1980).PubMedCrossRefGoogle Scholar
  73. 73.
    A. J. Morgan, J. R. North, and M. A. Epstein, Purification and properties of the gp340 component of Epstein-Barr (EB) virus membrane antigen (MA) in an immunogenic form, J. Gen. Virol., 64: 445 (1983).CrossRefGoogle Scholar
  74. 74.
    B. J. Randle, A. J. Morgan, S. A. Stripp, and M. A. Epstein, Large-scale purification of Epstein-Barr virus membrane antigen gp340 using a monoclonal immunoabsorbent, J. Immunological Methods, 77: 25 (1985).CrossRefGoogle Scholar
  75. 75.
    B. Morein, A. Helenius, K. Simons, R. Pettersson, L. Kääriäinen, and V. Schirrmacher, Effective subunit vaccines against an enveloped animal virus, Nature, 276: 715 (1978).PubMedCrossRefGoogle Scholar
  76. 76.
    E. K. Manesis, C. H. Cameron, and G. Gregoriadis, Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen, FEBS Lett., 102: 107 (1979).PubMedCrossRefGoogle Scholar
  77. 77.
    B. J. Randle, and M. A. Epstein, A highly sensitive enzyme-linked immunosorbent assay to quantitate antibodies to Epstein-Barr virus membrane antigen gp340, J. Virological Methods, 9: 201 (1984).CrossRefGoogle Scholar
  78. 78.
    M. J. Crumpton, and D. Snary, Preparation and properties of lymphocyte plasma membrane, Contemp. Topics Mol. Immunol., 3: 27 (1974).CrossRefGoogle Scholar
  79. 79.
    M. A. Epstein, A. J. Morgan, S. Finerty, B. J. Randle, and J. K. Kirkwood, Protection of cotton-top tamarins against EB virus-induced malignant lymphoma by a prototype subunit vaccine, Nature, in press (1985).Google Scholar
  80. 80.
    M. A. Epstein, B. J. Randle, S. Finerty, and J. K. Kirkwood, Not all potently neutralizing, vaccine-induced antibodies to EB virus ensure protection of susceptible experimental animals, submitted to press (1985).Google Scholar
  81. 81.
    W. Henle, and G. Henle, Seroepidemiology of the virus, in: The Epstein-Barr virus“, M. A. Epstein, and B. G. Achong, eds., Springer, Heidelberg and New York (1979).Google Scholar
  82. 82.
    C. M. Edson, and D. A. Thorley-Lawson, Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus, J. Virol., 46: 547 (1983).PubMedGoogle Scholar
  83. 83.
    A. J. Morgan, A. R. Smith, R. N. Barker, and M. A. Epstein, A structural investigation of the Epstein-Barr (EB) virus membrane antigen glycoprotein, gp340, J. Gen. Virol., 65: 397 (1984).PubMedCrossRefGoogle Scholar
  84. 84.
    M. Hummel, D. A. Thorley-Lawson, and E. Kieff, An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200), J. Virol., 49: 413 (1984)PubMedGoogle Scholar
  85. 85.
    M. Biggin, P. J. Farrell, and B. G. Barrell, Transcription and DNA sequence of the BamHI L fragment of B95–8 Epstein-Barr virus, EMBO J., 3: 1083 (1984).PubMedGoogle Scholar
  86. 86.
    G. L. Smith, M. Mackett, and B. Moss, Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen, Nature, 302: 490 (1983).PubMedCrossRefGoogle Scholar
  87. 87.
    B. Moss, G. L. Smith, J. L. Gerin, and R. H. Purcell, Live recombinant vaccinia virus protects chimpanzees against hepatitis B, Nature, 311: 67 (1984).PubMedCrossRefGoogle Scholar
  88. 88.
    M. Mackett, T. Yilma, J. K. Rose, and B. Moss, Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle, Science, 227: 433 (1985).PubMedCrossRefGoogle Scholar
  89. 89.
    B. Morein, B. Sundquist, S. Höglund, K. Dalsgaard, and A. Osterhaus, Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses, Nature, 308: 457 (1984).PubMedCrossRefGoogle Scholar
  90. 90.
    J. C. Niederman, A. S. Evans, L. Subrahmanyan, and R. W. McCollum, Prevalence, incidence and persistence of EB virus antibody in young adults, New Engl. J. Med., 282: 361 (1970).Google Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • M. A. Epstein
    • 1
  1. 1.Nuffield Department of Clinical Medicine, University of OxfordJohn Radcliffe Hospital HeadingtonOxfordUK

Personalised recommendations